AzTrials
AzTrials

HealthyPhase 1MDRNCT04849013

Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness

A Phase 1 study testing Mescaline 100mg, Mescaline 200mg and Mescaline 400mg in people with Healthy, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Mescaline (the active substance in Peyote and San Pedro cacti) is a classic and long known serotonergic psychedelic substance (hallucinogen) that is widely used for recreational, spiritual, and/or ethno medical purposes. Despite its long history, modern data on the acute effects of mescaline on human is lacking. Read more about this study

Who is it for?
Ages 25 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Healthy
What is being tested?
Mescaline 100mg, Mescaline 200mg and Mescaline 400mg
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
16 participants
Where
1 siteSwitzerland
Study dates
11 Aug 2021to 27 Mar 2023
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 25 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Age between 25 and 65 years old
  • Sufficient understanding of the German language
  • Understanding of procedures and risks associated with the study
  • Willing to adhere to the protocol and signing of the consent form
  • Willing to refrain from the consumption of illicit psychoactive substances during the study
  • Abstaining from xanthine-based liquids from the evenings prior to the study sessions to the end of the study days
Show all 9Show fewer
  • Willing not to drive a traffic vehicle or operate heavy machinery within 48 hours after substance administration
  • Willing to use double-barrier birth control throughout study participation
  • Body mass index between 18-29 kg/m2

Who cannot join

  • Chronic or acute medical condition
  • Current or previous major psychiatric disorder
  • Psychotic disorder or bipolar disorder in first-degree relatives
  • Hypertension (>140/90 mmHg) or hypotension (SBP10 cigarettes/day)
  • Hallucinogenic substance use (not including cannabis) more than 20 times or any time within the previous two months
  • Pregnancy or current breastfeeding
Show all 10Show fewer
  • Participation in another clinical trial (currently or within the last 30 days)
  • Use of medication that may interfere with the effects of the study medication
  • Tobacco smoking (>10 cigarettes/day)
  • Consumption of alcoholic beverages (>20 drinks/week)

Trial locations and contacts

1 site in 1 country.

Switzerland1 site
  • University Hospital Basel, Clinical Trial Unit

    Basel, Canton of Basel-City, 4056

Other trials in Switzerland

About this study

Mescaline (the active substance in Peyote and San Pedro cacti) is a classic and long known serotonergic psychedelic substance (hallucinogen) that is widely used for recreational, spiritual, and/or ethno medical purposes. Despite its long history, modern data on the acute effects of mescaline on human is lacking. Mescaline produces prototypical psychedelic effects, similar as lysergic acid diethylamide (LSD) and psilocybin. The serotonin 2A (5-HT2A) receptor is thought to primarily mediate acute alterations of consciousness induced by LSD and psilocybin. However, the contributory role of the 5-HT2A receptor in mescaline-induced alterations of consciousness is unclear. Using 5-HT2A receptor antagonist ketanserin, the psychedelic experience induced by LSD and psilocybin can be attenuated and shortened. The present study therefore explores the role the 5-HT2A receptor in mescaline-induced altered states of consciousness using escalating doses of mescaline and the 5-HT2A receptor blocker ketanserin administered before a high dose of mescaline.

Objective: The present MDR-study will characterize the subjective effects of different doses of mescaline using modern psychometric instruments and examine the contribution of the 5-HT2A receptor in the mescaline-induced alterations of consciousness.

Read more

Design: Double-blind, placebo-controlled, 6-period cross-over design with six treatment conditions. 1) Placebo (Pla + Pla), 2) 100 mg mescaline (Pla + 100mg mescaline), 3) 200 mg mescaline (Pla + 200mg mescaline), 4) 400 mg mescaline (Pla + 400mg mescaline), 5) 800 mg mescaline (Pla + 800mg mescaline), and 6) 40mg ketanserin and 800mg mescaline (Ket + 800mg mescaline).

Participants: 16 healthy participants aged ≥ 25 and ≤ 65 years (8 female, 8 male)

Conditions
Healthy
Being tested
Placebo, Mescaline 100mg, Mescaline 200mg, Mescaline 400mg, Mescaline 800mg
Keywords
Mescaline, Serotonin, Hallucinogen

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PlaceboDrug

    Drug: Placebo Capsules containing mannitol looking identical to the other drugs Other: Placebo Capsules containing mannitol looking identical to the other drugs

  • Mescaline 100mgDrug

    Drug: 100mg Mescaline per os, single dose

    Other: Placebo (Capsules containing mannitol looking identical to the other drugs)

  • Mescaline 200mgDrug

    Drug: 200mg Mescaline per os, single dose

    Other: Placebo (Capsules containing mannitol looking identical to the other drugs)

  • Mescaline 400mgDrug

    Drug: 400mg Mescaline per os, single dose

    Other: Placebo (Capsules containing mannitol looking identical to the other drugs)

  • Mescaline 800mgDrug

    Drug: 800mg Mescaline per os, single dose

    Other: Placebo (Capsules containing mannitol looking identical to the other drugs)

  • Mescaline 800mg + Ketanserin 40mgDrug

    Drug: 800mg Mescaline per os, single dose

    Other: 40mg Ketanserin per os, single dose

Study groups in NCT04849013
Study groupRoleWhat they receive
Placebo + PlaceboPlacebo comparatorNot described
Receives: Drug: Placebo
Mescaline-100 + PlaceboActive comparatorNot described
Receives: Drug: Mescaline 100mg
Mescaline-200 + PlaceboActive comparatorNot described
Receives: Drug: Mescaline 200mg
Mescaline-400 + PlaceboActive comparatorNot described
Receives: Drug: Mescaline 400mg
Mescaline-800 + PlaceboActive comparatorNot described
Receives: Drug: Mescaline 800mg
Mescaline-800 + KetanserinActive comparatorNot described
Receives: Drug: Mescaline 800mg + Ketanserin 40mg

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Altered States of Consciousness

    5 Dimensions of Altered States of Consciousness (5D-ASC) assesses mood, anxiety, derealization, depersonalization, changes in perception, auditory alterations, and reduced vigilance. The questionnaire is consisting of 94 items to be rated on a visual analog scale (horizontal line, 100 mm, marked with "not at all" on the left and "extremely" on the right), with higher values indicating stronger effects. Subjects will mark the scale with vertical lines.

    Measured: 18 months

Secondary outcomes (28)
  1. Extent of subjective response over time

    Visual Analog Scales (VAS) will be repeatedly used to assess subjective alterations in consciousness over time. VAS will be presented as 100 mm long horizontal lines marked with "not at all" on the left and "extremely" on the right. The following VAS will be used: "any drug effect", "good drug effect", "bad drug effect", "stimulated", "happy", "anxiety", "nausea", "alteration of vision", "alterations of hearing", "sounds seem to influence what I see", "alteration of sense of time", "the boundaries between myself and my surroundings seem to blur", "I am having insights into connections that previously puzzled me", "open", "talkative", and "trust". Subjects will mark the scale with vertical lines.

    Measured: 18 months

  2. Subjective mood ratings

    Adjective Mood Rating Scale (AMRS) assesses the occurrence and intensity of 60 moods on a 4-point Likert scale ranging from "not at all" to "extremely".

    Measured: 18 months

  3. Subjective experiences of spiritual phenomenons

    Spiritual Realms Questionnaire (SRQ) assesses the spiritual phenomenons elicited by psychedelic substances through 11 main questions to be answered on a total of 65 sub-ordered visual analog scales (horizontal line, 100 mm, marked with "no, at all" on the left and "yes, very strong" on the right).

    Measured: 18 months

  4. States of Consciousness

    States of Consciousness Questionnaire (SCQ) assesses the emergence and intensity of phenomenons occurring in altered states of consciousness on a 6-point Likert scale ranging from 0 ("not at all") to 5 ("extremely").

    Measured: 18 months

  5. Mystical-type experiences

    Mystical-type experience questionnaire (MEQ) assesses with 30 items (embedded into the SCQ) the mystical experiences on a 6-point Likert scale ranging from 0 ("not at all") to 5 ("extremely").

    Measured: 18 months

  6. Blood pressure

    Blood pressure, assessed 20 times during each study session via systolic and diastolic blood pressure.

    Measured: 18 months

  7. Heart rate

    Heart rate, assessed 20 times during each study session via heart rate, Emax.

    Measured: 18 months

  8. Body temperature

    Body temperature assessed 20 times during each study session via tympanic body temperature.

    Measured: 18 months

  9. Pupil size

    Pupil size, assessed 8 times during each study session via pupilometer.

    Measured: 18 months

  10. Mescaline concentrations in the blood

    Mescaline and metabolites concentrations measured in the blood plasma, assessed 20 times during each study session via blood samples.

    Measured: 18 months

  11. Mescaline concentrations in the urine

    Mescaline and metabolites concentration measured in the urine, assessed in the total amount collected during each study session.

    Measured: 18 months

  12. Effects on brain-derived neurotrophic factor (BDNF)

    Plasma levels of brain-derived neurotrophic factor (BDNF), assessed 5 times during each study session via blood samples.

    Measured: 18 months

  13. Effects on inflammatory cytokines

    Plasma levels of INF-gamma, TNFalpha, Interleukins, assessed 5 times during each study session via blood samples.

    Measured: 18 months

  14. Effects on oxytocin

    Plasma levels of oxytocin, assessed 4 times during each study session via blood samples.

    Measured: 18 months

  15. Emotional effects

    Multifaceted Empathy Test (MET), effects on empathy in computer tests, assessed one time during each study session.

    Measured: 18 months

  16. Effect moderation through personality traits I

    Assessed one time during the screening via the NEO-Five-Factor-Inventory (NEO-FFI). The NEO-FFI assesses 5 personality traits (openness to experience, conscientiousness, extraversion, agreeableness and neuroticism) consisting of of 60 items. Each item is evaluated on a scale from -- "strong disagreement" to ++ "strong agreement".

    Measured: 18 months

  17. Effect moderation through personality traits II

    Assessed one time during the screening via Freiburger Personality Inventory (FPI). The FPI-R version comprises 138 items and covers 12 dimensions of personality: life satisfaction, social orientation, performance orientation, inhibition, excitability, aggressiveness, stress, physical complaints, health concerns, openness, as well as the secondary factors according to Eysenck's Extraversion and Emotionality (Neuroticism). It uses a 2-point scale ("true" and "not true").

    Measured: 18 months

  18. Effect moderation through personality traits III

    Assessed one time during the screening via Saarbrücker Personality Questionnaire (SPF). The SPF defines empathy as the "reactions of one individual to the observed experiences of another." It assesses 28-items on a 5-point Likert scale ranging from "Does not describe me well" to "Describes me very well". The measure has 4 subscales (Perspective Taking, Fantasy, Empathic Concern, Personal Distress) each made up of 7 different items.

    Measured: 18 months

  19. Effect moderation through personality traits IV

    Assessed one time during the screening via HEXACO personality inventory (Honesty-Humility, Emotionality, Extraversion, Agreeableness, Conscientiousness, and Openness). The HEXACO consists of 100 items. Each item is evaluated on a scale from 1 "strong disagreement" to 5 "strong agreement".

    Measured: 18 months

  20. Effect moderation through personality traits V

    Assessed one time during the screening via Defense Style Questionnaire (DSQ-40). The DSQ-40 can provide scores for 20 individual defenses, and scores for the three factors "mature", "neurotic", and "immature". Each item is evaluated on a scale from 1 to 9, where "1" indicates "completely disagree" and "9" indicates "fully agree".

    Measured: 18 months

  21. Psychological insight

    Psychological insight questionnaire (PIQ), assesses painful insights during a psychedelic experience with 14 items (6-point Likert scale ranging from 0 ("not at all") to 5 ("extreme/more than ever before")).

    Measured: 18 months

  22. Effects on life satisfaction, well-being and appreciation I

    Scale of Positive and Negative Experience (SPANE), assesses life satisfaction regarding the preceding week with12 items (5-point Likert scale ranging from 1 ("very rarely") to 5 ("very often")).

    Measured: 18 months

  23. Effects on life satisfaction, well-being and appreciation II

    Berner Subjective Well-Being Questionnaire for Adolescents (BFW/E), assesses optimism with 8 items (6-point Likert scale ranging from 1 ("completely wrong") to 6 ("completely right")).

    Measured: 18 months

  24. Effects on life satisfaction, well-being and appreciation III

    Global Life Satisfaction (GLS), assesses life satisfaction with a single question (ranging from 0 ("not at all satisfied") to 10 ("entirely satisfied")).

    Measured: 18 months

  25. Effects on life satisfaction, well-being and appreciation IV

    Appreciation Scale (AS), assesses appreciation with 57 questions (7-point Likert scale ranging from 1 ("never") to 7 ("several times a day")).

    Measured: 18 months

  26. Incidence of Adverse Events before and during each study session

    Major adverse events concerning the subject's health during study inclusion (if present) are registered by semi-structured interviews.

    Measured: 18 months

  27. Incidence of Adverse Events during each study session

    List of complaints (LC), which covers the emergence of 66 complaints in a yes/no format, assessed three times during each study session.

    Measured: 18 months

  28. Electrical activity of the heart

    Electrocardiogram (ECG) will be recorded twice during the study sessions (baseline and at peak drug effect) as well as on the screening exam to assess potential drug effects on the QTc interval.

    Measured: 18 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Apr 2021
  2. Study start11 Aug 2021
  3. Primary completion27 Mar 2023
  4. Study completion27 Mar 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Crossover
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
16 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04849013
Sponsor's protocol ID
BASEC 2021-00035
Acronym
MDR
Status last verified
Mar 2023
First submitted
26 Mar 2021
Last updated
29 Mar 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Mueller L, Klaiber A, Ley L, Becker AM, Thomann J, Luethi D, Schmid Y, Liechti ME. Pharmacokinetics, Pharmacodynamics, and Urinary Recovery of Oral Mescaline Hydrochloride in Healthy Participants. Clin Pharmacokinet. 2025 Oct;64(10):1495-1506. doi: 10.1007/s40262-025-01544-x. Epub 2025 Jul 14.

    PubMed 40658345

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Mescaline 100mg, Mescaline 200mg and Mescaline 400mg in people with Healthy, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 29 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Altered States of Consciousness (time frame: 18 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04849013, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Mar 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in